DDInter734 DDInter1027
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing cardiovascular disorders. Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically implicated in their vasoconstrictive activity.[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without causing vasoconstriction.[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class of anti-migraine medications in which lasmiditan is the first and only member: the neurally-acting anti-migraine medications (NAAMAs).[A187322,A187307]
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Cimetidine
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Lasmiditan
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Lasmiditan
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Fidaxomicin (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Doxepin (Compound) and Doxepin may lead to a major life threatening interaction when taken with Lasmiditan
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound) and Doxepin may lead to a major life threatening interaction when taken with Lasmiditan